NEUROLITE
LOE Approachingbicisate dihydrochloride
NDAINJECTIONINJECTABLE
Approved
Nov 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NEUROLITE (bicisate dihydrochloride) is clinical pharmacology general neurolite®, kit for the preparation of technetium tc99m bicisate for injection forms a stable, lipophilic complex which can cross the blood brain barrier. First approved in 1994.
Drug data last refreshed 10h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEUROLITE is a Technetium Tc99m-labeled imaging agent that forms a stable, lipophilic complex capable of crossing the blood-brain barrier via passive diffusion. It is used for cerebral imaging, particularly in stroke evaluation, where it localizes to brain tissue based on regional perfusion and cellular uptake. The agent remains stable in the brain for approximately 6 hours, with optimal imaging occurring 30-60 minutes post-injection.
LOE Approaching
As a product approaching loss of exclusivity (LOE) after 30 years on market, the brand team is likely focused on lifecycle management and transition planning rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY General Neurolite®, Kit for the Preparation of Technetium Tc99m Bicisate for Injection forms a stable, lipophilic complex which can cross the blood brain barrier. Technetium Tc99m Bicisate crosses intact cell membranes and the intact blood brain barrier by passive diffusion.…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.